September 14th was an important milestone in the march towards Open Banking. It marked the original deadline for implementation of PSD2 or ‘the second Payment Services Directive.’ If you don’t know what that is, and you are currently purchasing (or thinking of purchasing) European consumer transactional data – you may want to read on. In this report, we introduce the ubiquitous, yet often poorly understood, FinTech phenomenon of Open Banking, and consider the implications of these regulations on both buyers and sellers of alternative data.

In the following Intelligence piece, we explore healthcare claims and electronic health records (EHRs) as alternative data sources for investors. Healthcare claims and EHRs can offer valuable insights into drug/medical device prescribing and utilisation trends. This information has clear applications for investors in pharmaceutical, biotech, and medical device/equipment companies as well as companies responsible for paying healthcare claims such as managed care organisations or other health insurers.

Accounting scandals can lead to crippling losses for the uninformed investor - from the Enron and Worldcom scandals to the more recent fraudulent activity of Kangde Xin and Kangmei in China. This article considers the ever-increasing influence of Chinese capital markets, company-level risk factors for financial misreporting, as well as how investors can use alternative data sources to detect early signs of malfeasance by China-listed companies.

Last week, it was announced that leading telehealth provider, Teladoc (NYSE: TDOC), observed a 33% increase in share price and a 40% increase in revenue, year to date. At Neudata, we thought it would be as good a time as any to discuss some alternative datasets that could help investors predict some key metrics of telehealth companies.

Didn’t anyone ever tell you that you shouldn’t believe everything you read? In the following intelligence piece, we consider the 21st-century crisis of fabricated content and its implications for users of alternative data. Leave your MAUs at the door and join us in the strange world of app download fraud, review fabrication, and bot-generated content.

We previously highlighted a study which found that institutional investors are using Freedom of Information Act (FOIA) requests – specifically, FDA FOIA requests - to generate abnormal returns. In this piece, we provide three examples of how investors have successfully utilised this FOIA technique to obtain early access to stock-moving information.

It is no secret that the current alternative data market heavily services public equity investors. Of course, these are some of the biggest alt data spenders, so such preferential treatment isn’t surprising. However, this bias leads us to believe that non-equity investors may assume that alt data isn’t relevant to their strategies. Unsurprisingly, we believe otherwise. In this report we take a look at the alternative data options for real estate investors. Specifically, we address 1) issues with using traditional datasets and 2) which alternative datasets could help provide more accurate KPIs.